Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ADICET BIO INC (ACET) Stock Price & Overview
NASDAQ:ACET • US0070022076
Current stock price
8.2 USD
+0.65 (+8.61%)
At close:
8.04 USD
-0.16 (-1.95%)
After Hours:
The current stock price of ACET is 8.2 USD. Today ACET is up by 8.61%. In the past month the price increased by 17.31%. In the past year, price decreased by -23.51%.
ACET Key Statistics
52-Week Range6.01 - 17.4384
Current ACET stock price positioned within its 52-week range.
1-Month Range6.05 - 8.79
Current ACET stock price positioned within its 1-month range.
- Market Cap
- 78.72M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -17.98
- Dividend Yield
- N/A
ACET Stock Performance
Today
+8.61%
1 Week
+3.80%
1 Month
+17.31%
3 Months
+2.63%
Longer-term
6 Months -31.67%
1 Year -23.51%
2 Years -64.66%
3 Years -90.65%
5 Years -96.18%
10 Years N/A
ACET Stock Chart
ACET Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ACET. When comparing the yearly performance of all stocks, ACET is a bad performer in the overall market: 80.74% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ACET Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACET. ACET has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ACET Earnings
Next Earnings DateMay 4, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$2.94
Revenue Reported
EPS Surprise -2.87%
Revenue Surprise %
ACET Forecast & Estimates
13 analysts have analysed ACET and the average price target is 54.06 USD. This implies a price increase of 559.27% is expected in the next year compared to the current price of 8.2.
Analysts
Analysts86.15
Price Target54.06 (559.27%)
EPS Next Y41.99%
Revenue Next YearN/A
ACET Financial Highlights
Over the last trailing twelve months ACET reported a non-GAAP Earnings per Share(EPS) of -17.98. The EPS increased by 16.14% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-116.80M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.72% | ||
| ROE | -73.36% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%42.58%
Sales Q2Q%N/A
EPS 1Y (TTM)16.14%
Revenue 1Y (TTM)N/A
ACET Ownership
Ownership
Inst Owners58.98%
Shares9.60M
Float8.67M
Ins Owners0.19%
Short Float %6.9%
Short Ratio4.4
ACET Industry Overview
ACET operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
ACET Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACET
Company Profile
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2018-01-26. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Company Info
IPO: 2018-01-26
ADICET BIO INC
131 Dartmouth Street, 3Rd Floor
Boston MASSACHUSETTS 02116 US
CEO: Chen Schor
Employees: 102
Phone: 16174822333
ADICET BIO INC / ACET FAQ
What does ACET do?
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2018-01-26. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Can you provide the latest stock price for ADICET BIO INC?
The current stock price of ACET is 8.2 USD. The price increased by 8.61% in the last trading session.
Does ACET stock pay dividends?
ACET does not pay a dividend.
What is the ChartMill rating of ADICET BIO INC stock?
ACET has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is ADICET BIO INC worth?
ADICET BIO INC (ACET) has a market capitalization of 78.72M USD. This makes ACET a Micro Cap stock.
Can you provide the ownership details for ACET stock?
You can find the ownership structure of ADICET BIO INC (ACET) on the Ownership tab.